Go to Top

Biotech News

Idenix Pharmaceuticals (IDIX): Collaboration With Janssen to Initiate Phase II Simeprevir, IDX719 and TMC647055 Studies

Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) is engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Building on its expertise in nucleoside chemistry and other small molecule chemistry and biology, the company is well positioned to become a leader in antiviral pharmaceuticals. Idenix’s current focus is on …Read More

Celsion (CLSN): Cash and Incentives up to $100 Million

Celsion (NASDAQ: CLSN) is developing a ThermoDox, a treatment for primary liver cancer. The company combines radio-frequency thermal ablation (RFA) with a high dose of the drug doxorubin. ThermoDox targets a specific area and then cover the tumor through the process of heating the accumulated drug. Phase III results show that ThermoDox with RFA treatment improves the …Read More

Kips Bay Medical (KIPS): FDA Approval for eMESH Additional US Study

Kips Bay Medical,Inc. (NASDAQ: KIPS) is dedicated to providing therapeutic vascular technologies for the cardiac surgeon to better treat cardiovascular disease. Recently KIPS announced that the United States Food & Drug Administration (FDA) has granted approval for additional US patients to be enrolled in Kips Bay Medicals eMESH I clinical feasibility trial of its eSVS …Read More

Protalix BioTherapeutics (PLX): Offer of Potential All-Cash Acquisition

Protalix BioTherapeutics, Inc. (PLX) is a biopharmaceutical company that is revolutionizing the development and manufacturing of recombinant therapeutic proteins through its ProCellEx® plant cell-based protein expression system. Using ProCellEx, Protalix is focused on the development and commercialization of a proprietary pipeline of novel and biosimilar proteins that target large, established pharmaceutical markets and that rely …Read More

Exelixis, Inc. (NASDAQ: EXEL): COMETRIQ Availability in the U.S.

Exelixis, Inc. (NASDAQ: EXEL) is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. Exelixis announced on Thursday the commercial availability of COMETRIQ® (cabozantinib) for the treatment of patients with progressive, metastatic medullary thyroid cancer approved by FDA on November 29, 2012. COMETRIQ (cabozantinib) is being distributed exclusively …Read More

Acadia Pharmaceuticals (ACAD): Elected BOD Member

Acadia Pharmaceuticals (ACAD) is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. Acadia’s lead product candidate, pimavanserin, is in Phase III development . Pimavanserin is projected to be a potential first-in-class treatment for Parkinson’s disease psychosis. On January 18, 2013, Acadia’s Board of …Read More

Threshold Pharmaceuticals (THLD): Merck KGaA Initiated the Global Phase 3 MAESTRO Study

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) is a clinical stage biopharmaceutical company focused on the discovery and development of cancer therapeutics based on a novel and powerful approach of targeting tumor hypoxia. THLD today announced that Threshold’s partner Merck KGaA, Darmstadt, Germany, through its division Merck Serono, initiated the global Phase 3 MAESTRO study assessing the …Read More

NuPathe Inc. (NASDAQ: PATH): FDA Approval of the Zecuity

NuPathe Inc. (PATH) today announced that the U.S. Food and Drug Administration (FDA) has approved Zecuity™ (sumatriptan iontophoretic transdermal system) for the acute treatment of migraine with or without aura in adults. Zecuity is a single-use, battery-powered patch that actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin. Zecuity provides relief of …Read More

Neuralstem (CUR): FDA Approval for the Phase 1 Trial of NSI-566

Neuralstem’s (CUR) patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. In August 2012, Neuralstem completed the final surgery of an FDA-approved Phase I NSI-566 …Read More

Telik, Inc. (TELK): Telintra Granted Orphan Drug Designation by the FDA

Telik, Inc. (TELK) is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. Telik’s product candidates are: TELINTRA® (TLK199) is in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia TELCYTA® (TLK286) is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase …Read More